

# Risperidone

---

## Selected References:

- Accessdata.fda.gov. (2009). Highlights of Prescribing Information – Risperidone. Retrieved from [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2009/020272s056,020588s044,021346s033,021444s031bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s031bl.pdf).
- Coppola D, et al. 2007. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. *Drug Saf*; 30(3):247-64.
- Damkier P and Videbech P. 2018. The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review. *CNS Drugs* 32:351-366.
- Eberhard J., et al. 2007. Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. *Acta Psychiatrica Scandinavica*. 115(4), 268-276.
- Ennis ZN and Damkier P. 2014. Pregnancy Exposure to Olanzapine, Quetiapine, Risperidone, Aripiprazole and Risk of Congenital Malformation. A Systemic Review. *Basic & Clinical Pharmacology & Toxicology* 116:315-320.
- Elstein Y, et al. 2004. Pregnancies in Gaucher disease: a 5 -year study. *Am J Obstet Gynecol* 190:435-441.
- Habermann F, et al. 2013. Atypical Antipsychotic Drugs and Pregnancy Outcome: A Prospective, Cohort Study. *J Clin Psychopharmacol* 33:453-62.
- Huybrechts KF, et al. 2016. Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. *JAMA Psychiatry* 73(9): 938-946.
- McAllister-Williams RH, et al. 2017. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. *J Psychopharmacol*; 31(5): 519-552.
- Park Y, et al. 2018. Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes. *Am J Psychiatry* 175(6):564-574.
- Petersen I, et al. 2016. Risks and Benefits of Psychotropic Medication in Pregnancy: Cohort Studies based on UK Electronic Primary Care Health Records. *Health Technol Assess* 20:1-176
- Straub L, et al. 2022. Association of antipsychotic drug exposure in pregnancy with risk of neurodevelopmental disorders: a national birth cohort study. *JAMA Intern Med* 182(5):522-533.
- Uguz F. 2016. Second-Generation Antipsychotics During the Lactation Period. *J Clin Psychopharmacol* 36(3):244-252.
- Uguz F. 2019. Adverse events in a breastfed infant exposed to risperidone and haloperidol. *Breastfeed Med.*;14:683-4.
- Vigod SN, et al. 2015. Antipsychotic Drug Use In Pregnancy: High Dimensional, Propensity Matched, Population Based Cohort Study. *BMJ* 350:h2298.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2024.

# Risperidone

## Selected References:

- Berle JO, et al. 2004. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome P450 genotypes. *J Clin Psychiatry* 65:1228-34. PMID: 15367050
- Briggs G, et al. 2022. *Drugs in Pregnancy and Lactation: Wolters Kluwer; 12th edition: 950-951*
- Brunel P, et al. 1994. [Follow-up of 151 pregnant women exposed to antidepressant treatment (MAOI excluded) during organogenesis.] *Therapie* 49:117-122.
- Eggermont E. 1973. Withdrawal symptoms in neonate associated with maternal imipramine therapy. *Lancet* 2:680.
- Misri S & Sivertz K. 1991. Tricyclic drugs in pregnancy and lactation: a preliminary report. *Int J Psychiatry Med* 21(2):157-71.
- Grzeskowiak, LE, et al. 2022. Perinatal antidepressant use and breastfeeding outcomes: Findings from the Norwegian Mother, Father and Child Cohort Study. *Acta Obstetrica et Gynecologica Scandinavica*. 101(30): 344-54.
- Mitchell JE and Popkin MK: Antidepressant drug therapy and sexual dysfunction in men: a review. *J Clin Psychopharm* 3:76-79, 1983.
- Nulman I, et al. 1997. Neurodevelopment of children exposed in utero to antidepressant drugs. *N Engl J Med* 336:258-62.
- Overo KF, et al. 1997. Interaction of perphenazine with the kinetics of nortriptyline. *Acta Pharmacol Toxicol*; 40:97-105.
- Schoretsanitis S, et al. 2020. The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis. *Expert Opin Drug Metab Toxicol*; 16(5):431-440.
- Semet, M., et al. 2017. The impact of drugs on male fertility: a review. *Andrology* 5(4): 640-663.
- Shearer WT, et al. 1972. Urinary retention in a neonate secondary to maternal ingestion of nortriptyline. *J Pediatr* 81:570-2.
- US Preventive Services Task Force, Curry SJ, et al. 2019. Interventions to Prevent Perinatal Depression: US Preventive Services Task Force Recommendation Statement. *JAMA* 321(6):580-587.
- Wall-Wieler, E, et al. 2020. Antidepressant use around conception, prepregnancy depression, and risk of ectopic pregnancy. *The Canadian Journal of Psychiatry*, 65(12):845-53.
- Webster PA. 1973. Withdrawal symptoms in neonates associated with maternal antidepressant therapy. *Lancet* 2(7824):318-9.
- Weissman AM, et al. 2004. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. *Am J Psychiatry* 161:1066-78.
- Wisner KL, et al. 2002. Postpartum depression. *N Engl J Med*. 347:194-9.

- Xing, D, et al. 2020. Maternal use of antidepressants during pregnancy and risks for adverse perinatal outcomes: a meta-analysis. *Journal of Psychosomatic Research*, 137:110231.

[¿Preguntas? Llame al 866.626.6847](#) | [Texto 855.999.3525](#) | [Correo electrónico o chat en MotherToBaby.org](#) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2024.

## Risperidone

### Selected References:

- American College of Obstetricians and Gynecologists. 2020. Prelabor Rupture of Membranes: ACOG Practice Bulletin, Number 217. *Obstetrics & Gynecology* 135(3):p e80-e97.
- Benyamini L, et al. 2005. The safety of amoxicillin/clavulanic acid and cefuroxime during lactation. *Ther Drug Monit* 27:499-502.
- Berkovitch M, et al. 2004. First-trimester exposure to amoxicillin/clavulanic acid: a prospective controlled study. *Br J Clin Pharmacol* 58:298-302.
- Campbell AC, et al. 1991. The excretion of amoxicillin in breastmilk and its effect on the suckling infant. *Br J Clin Pharmacol* 31:230p.
- Czeizel AE, et al. 2001. Augmentin treatment during pregnancy and the prevalence of congenital abnormalities: a population-based case-control teratologic study. *Eur J Obstet Gynecol Reprod Biol* 97:188-92.
- Daniel S, et al. 2019. The safety of amoxicillin and clavulanic acid use in the first trimester of pregnancy. *Br J Clin Pharmacol* 85:2856-63.
- Grantham J, et al. 2002. Association between co-amoxiclav used antenatally with necrotising enterocolitis in the neonate. *Am J Obstet Gynecol* 187:S90.
- Jepsen P, et al. 2003. A population-based study of maternal use of amoxicillin and pregnancy outcome in Denmark. *Br J Clin Pharmacol* 55:216-221.
- Kafetzis D, et al. 1981. Passage of cephalosporins and amoxicillin into the breast milk. *Acta Paediatr Scand* 70:285-8.

- Kenyon SL, et al. 2001. ORACLE Collaborative Group. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. *Lancet* 357:979-88.
- Kenyon SL, et al. 2001. ORACLE Collaborative Group. Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial. *Lancet* 357:989-94.
- Kenyon S, et al. 2002. ORACLE-antibiotics for preterm prelabour rupture of the membranes: short-term and long-term outcomes. *Acta Paediatr Suppl* 437:12-15.
- Kenyon S, et al. 2008. Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial. *Lancet* 372 (9646):1319-27.
- Kenyon S, et al. 2013. Preterm Labour, Antibiotics and Cerebral Palsy. Scientific Impact Paper No.33, Royal College of Obstetrics and Gynaecologists.
- Lin KJ, et al. 2012. Maternal exposure to amoxicillin and the risk of oral clefts. *Epidemiology* 23(5):699-705.
- Marlow N, et al. 2017. The ORACLE Children Study: educational outcomes at 11 years of age following antenatal prescription of erythromycin or co-amoxiclav. *Arch Dis Child Fetal Neonatal Ed* 102(2):F131-F135.
- Meeraus WH, et al. 2015. Association between antibiotic prescribing in pregnancy and cerebral palsy or epilepsy in children born at term: A cohort study using the health improvement network. *PLoS ONE* 10(3):e0122034.
- Mercer BM, et al. 1997. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. *JAMA* 278:989-995.
- Merkel TA, et al. 2014. Predicting disease severity of necrotizing enterocolitis: how to identify infants for future novel therapies. *J Clin Neonatol* 3(1):1-9.
- Padberg, S. 2015. Anti-infective Agents. In C Schaefer, P Peters, R Miller (Eds.), *Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment*. Pg 116. London: Elsevier.
- Puho EH, et al. 2007. Drug treatment during pregnancy and isolated orofacial clefts in Hungary. *Cleft Palate Craniofac J* 44:194-202.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

---

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2024.

# Risperidone

---

## Selected References:

- ACOG Committee Opinion No 804. 2020. Physical Activity and Exercise During Pregnancy and the Postpartum Period. *Obstet Gynecol*; *Obstet Gynecol*; 135(4):e178-188.
- 2022. Exercise During Pregnancy. Frequently asked questions. Available at: <https://www.acog.org/womens-health/faqs/exercise-during-pregnancy> [Accessed 3/2024].
- Artal R. 2016. Exercise in Pregnancy: Guidelines. *Clinical Obstetrics and Gynecology*; 59(3):639-644.
- Barakat R & Perales M. 2016. Resistance Exercise in Pregnancy and Outcome. *Clin Obstet Gynecol*; 59 (3):591-9.
- Claiborne, A, et al. 2023. A narrative review of exercise dose during pregnancy. *Birth Defects Research*, 115(17), 1581-1597
- Clapp III J, et al. 1999. Neonatal behavioral profile of the offspring of women who continued to exercise regularly throughout pregnancy. *Am J Obstet Gynecol*; 180(1):91-94.
- Clapp III J, et al. 2002. Continuing regular exercise during pregnancy: Effect of exercise volume on fetoplacental growth. *Am J Obstet Gynecol*; 186(1):142-147.
- Cordero Y, et al. 2015. Exercise is associated with a reduction in gestational diabetes mellitus. *Med Sci Sports Exerc*; 47: 1328 – 33.
- Fly AD, et al. 1998. Major mineral concentrations in human milk do not change after maximal exercise testing. *Am J Clin Nutr*; 68:345-9.
- Kennelly M, et al. 2002. Exercise-related changes in umbilical and uterine artery waveforms as assessed by Doppler ultrasound scans. *Am J Obstet Gynecol*; 187(1):661-666.
- Kennelly M, et al. 2002. Fetal heart rate response to strenuous maternal exercise: not a predictor of fetal distress. *Am J Obstet Gynecol*; 187(3):811-816.
- Kołomańska-Bogucka D, Mazur-Bialy AI. 2019. Physical Activity and the Occurrence of Postnatal Depression-A Systematic Review. *Medicina (Kaunas)*; 55(9):560.
- Lederman S, et al. 1999. Maternal body fat and water during pregnancy: Do they raise infant birth weight? *Am J Obstet Gynecol*; 180(1):235-240.
- Gascoigne EL, et al. 2023. Physical activity and pregnancy outcomes: an expert review. *Am J Obstet Gynecol MFM*; 5(1):100758.
- Gavard J & Artal R. 2008. Effect of Exercise on Pregnancy Outcome. *Clin Obstet Gynecol*; 51(2):467-480.
- Gregg VH & Ferguson JE. 2017. Exercise in Pregnancy. *Clin Sports Med Oct*;36(4):741-752.
- Greydanus DE & Patel DR. 2002. The female athlete: before and beyond puberty. *Pediatr Clin North Am* 49(3):553-580.
- Madsen M, et al. 2007. Leisure time physical exercise during pregnancy and the risk of miscarriage: a study within the Danish National Birth Cohort. *BJOG*; 114(11):1419-1426.
- Minguez-Alarcon L, et al. 2014. Physical activity is not related to semen quality in young healthy men. *Fertil Steril* 102: 1103-1109.
- Mottola M, et al. 2018. No. 367-2019. Canadian Guideline for Physical Activity throughout Pregnancy. *J Obstet Gynaecol Can*; 40(11):1528-1537.
- Mussawar M, et al. 2012. The effect of physical activity on fertility: a mini-review. *F S Rep*; 4(2):150-158.
- Price BB, et al. 2012. Exercise in pregnancy: effect on fitness and obstetric outcomes-a randomized trial. *Med Sci Sports Exerc*; 44:2263 –2269.
- Sanabria-Martínez G, et al. 2019. Effects of physical exercise during pregnancy on mothers' and neonates' health: a protocol for an umbrella review of systematic reviews and metaanalysis of randomised controlled trials. *BMJ Open*; 9:e030162.
- Sobal J & Marquart LF. 1994. Vitamin/mineral supplement use among athletes: a review of literature. *Int J Sport*

Nutr 4(4):320-334.

- Stafne SN, Salvesen et al. 2012. Regular exercise during pregnancy to prevent gestational diabetes: a randomized controlled trial. *Obstet Gynecol.* 119(1):29-36.
- Tomic V, et al. 2013. The effect of maternal exercise during pregnancy on abnormal fetal growth. *Croat Med J.* 54(4):362-8.
- Zourtadani A, et al. 2015. The effect of physical exercise on postpartum fitness hormone and lipid levels: a randomized controlled trial in primiparous, lactating women. *Arch Gynecol Obstet* 291(3): 525-530.

[¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .](#)

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2024.

---

## Risperidone

---

### Selected References:

- Ambresin G, et al. 2004. Olanzapine excretion into breast milk: a case report. *J Clin Psychopharmacol*; 24(1):93-5.
- Aydin B, et al. 2015. Olanzapine and quetiapine use during breastfeeding: Excretion into breast milk and safe breastfeeding strategy. *J Clin Psychopharmacol*; 35:206-8.
- Betcher HK, et. al 2020. Psychotropic Treatment During Pregnancy: Research Synthesis and Clinical Care Principles. *J Womens Health* 29(3):310-318.
- Brunner E, et al. 2013. Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. *BMC Pharmacology & Toxicology*, 14, 1-8.
- Croke S, et al. 2003. Olanzapine excretion in human breast milk: estimation of infant exposure. *Int J Neuropsychopharmacol*; 5:243-7.
- Damkier P, et al. 2018. The safety of second-generation antipsychotics during pregnancy: a clinically-focused review. *CNS Drugs* 32:351-366.
- Einarson A & Boskovic R. 2009. Use and safety of antipsychotics during pregnancy. *Journal of Psychiatric*

Practice, 15, 183-192.

- Ellfolk M, et al. 2021. Second-generation antipsychotic use during pregnancy and risk of congenital malformations. *Eur J Clin Pharmacol.* 2021; 77(11): 1737-1745.
- Ennis ZN, et al. 2014. Pregnancy exposure to Olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations: A systemic review. *Basic & Clinical Pharmacology & Toxicology.* 116(4), 315-20.
- Friedman SH, et al. 2017. Atypical antipsychotic use and outcomes in an urban maternal mental health service. *Int J Psychiatry Med* 51(6): 521-533.
- Gilad O, et al. 2011. Outcome of infants exposed to olanzapine during breastfeeding. *Breastfeeding Medicine*, 6, 55-58. doi: 10.1089/bfm.2010.0027.
- Habermann F, et al. 2013. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. *J Clin Psychopharmacol.*33(4):453-62.
- Heinonen E, et al. 2022. Antipsychotic Use During Pregnancy and Risk for Gestational Diabetes: A National Register-Based Cohort Study in Sweden. *CNS Drugs.* 36:529-539.
- Huybrechts KF, et al. 2016. Antipsychotic use in pregnancy and the risk for congenital malformations. *JAMA Psychiatr;* 73(9):938-946.
- Johnson KC et al. 2012. Prenatal antipsychotic exposure and neuromotor performance during infancy. *Arch Gen Psychiatry.* 69(8):787-94.
- Kallen B, et al. 2013. The use of central nervous system active drugs during pregnancy. *Pharmaceuticals.* 6(10): 1221-1286.
- Kollu P, et al. 2023. Olanzapine Pharmacokinetics: A Clinical Review of Current Insights and Remaining Questions. *Pharmgenomics Pers Med.* 16:1097-1108.
- Manouilenko I, et al. 2018. Long-acting olanzapine injection during pregnancy and breastfeeding: a case report. *Arch Womens Ment Health;* 21(5):587-589
- McKenna K, et al. 2005. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. *Journal of Clinical Psychiatry,* 4, 444-449.
- Miller DE, Sebastian CS. 2005. Olanzapine-induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine: a case report. *J Clin Psychiat;* 66:269-270.
- Newport DJ, et al 2007. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes
- Pacchiarotti I, et al. 2016. Mood stabilizers and antipsychotics during breastfeeding: Focus on bipolar disorder. *Eur Neuropsychopharmacol;* 26:1562-78.
- Park Y, et al. 2018. Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes. *Psychiatry* 175(6):564-574.
- Reutfors J, et al. 2020 Antipsychotic drug use in pregnancy: A multinational study from 10 countries. *Schizophr Res* 220:106-115
- Rubakowski J, et al. 2019. Recommendations of the Poliksh Psychiatric Association regarding the treatment of affective disorders in women of childbearing age. Part II: Bipolar disorder. *Psychiatr Pol* 53(2):263-276
- Shao P, et al. 2015. Effects of Clozapine and other Atypical Antipsychotics on Infants Development Who Were Exposed to as Fetus: A Post-Hoc Analysis. *PLoS One;* 10(4).
- Teodorescu A, et al. 2017. Dilemma of treating schizophrenia during pregnancy: a case series and a review of literature. *BMC Psychiatry* 17(1):311.
- Vigod SN, et al. 2015. Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study. *BMJ;* 350:h2298.
- ZYPREXA (olanzapine) Label – [accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020592s062021086s040021253s048lbl.pdf)  
[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2014/020592s062021086s040021253s048lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020592s062021086s040021253s048lbl.pdf)

**¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .**

---

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2024.